For almost four years, Bristol-Myers Squibb Co investors have profited handsomely thanks to the company’s sharp focus on cancer. On Friday, they felt the other side of that concentrated bet.
The drop in the shares on Friday — the worst in more than 16 years — had as much to do with the failure of Bristol-Myers’s drug Opdivo in a clinical trial for lung cancer as it did with investors’ now-shaken confidence in the New York-based company’s ability to be the breakaway leader in the field. It was also a stark reminder of the risks of drug development.
No other large pharmaceutical company has recently focused on one disease area like Bristol-Myers has, in this case by targeting drugs that leverage the immune system to attack tumors. The trial results, which showed that Opdivo failed to do better than chemotherapy at keeping previously untreated patients’ cancer from progressing, have left the door open for competitors like Merck & Co, AstraZeneca PLC and Roche Holding AG.
Bristol-Myers shares were down 16 percent to US$63.28 at the close in New York. Merck gained 10 percent to US$63.86.
Immunotherapy is a market potentially worth billions of dollars a year — Opdivo is predicted by analysts to bring in US$10.7 billion in 2020, and the immune-system drugs are projected to make up almost half of Bristol-Myers’ sales by that time.
Lung cancer is the biggest killer in oncology, according to the American Cancer Society, and the drugs have thus far been largely approved for cancers that affect fewer patients.
Bristol-Myers does not have any plans to alter its focus just yet or diversify away from cancer.
“It is clear, because of our track record of success, the expectations are high,” chief executive officer Giovanni Caforio said in a telephone interview on Friday. “It does really not change our focus and it does not change the long-term potential of Opdivo; it does not impact our commitment to making immuno-oncology the central pillar of our strategy.”
Friday’s results also expose the difference between the development strategies at Bristol-Myers and Merck, which has a competing drug in the same class, called Keytruda.
Merck designed its study to exclude patients with lower levels of a key biomarker thought to predict response to the drug. While that meant a smaller market, it meant a higher probability of success — and the trial reported positive results in June. Bristol-Myers’ trial included patients with lower levels of the biomarker.
Caforio said Bristol-Myers is still pushing ahead in studying previously untreated patients, but with combination drugs that could help more patients respond to the treatments, rather than just the ones with the highest levels of biomarkers in their tumors. Those results might not be ready until 2018.
“Our strategy continues to be the best strategy,” Caforio said.
The expectation is “not that every single trial will work, and it’s not about who wins every time one trial is completed,” he said.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last